Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 3,551 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Follow-Up Questions
What is the price performance of DMPHF stock?
The current price of DMPHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Dermapharm Holding SE?
Dermapharm Holding SE belongs to Pharmaceuticals industry and the sector is Health Care
What is Dermapharm Holding SE market cap?
Dermapharm Holding SE's current market cap is $0
Is Dermapharm Holding SE a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Dermapharm Holding SE, including 2 strong buy, 6 buy, 3 hold, 0 sell, and 2 strong sell
